Recro Pharma (REPH) Earns Buy Rating from Oppenheimer

Oppenheimer restated their buy rating on shares of Recro Pharma (NASDAQ:REPH) in a research note published on Thursday morning.

Other research analysts have also recently issued research reports about the stock. ValuEngine raised shares of Recro Pharma from a sell rating to a hold rating in a report on Thursday, March 1st. Zacks Investment Research raised shares of Recro Pharma from a sell rating to a hold rating in a report on Wednesday, March 21st. UBS began coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They set an outperform rating for the company. Finally, CIBC began coverage on shares of Recro Pharma in a report on Wednesday, February 14th. They set an outperform rating and a $19.00 target price for the company. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Recro Pharma presently has a consensus rating of Buy and a consensus price target of $14.21.

How to Become a New Pot Stock Millionaire

NASDAQ:REPH opened at $10.19 on Thursday. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $12.23. The company has a current ratio of 1.75, a quick ratio of 1.55 and a debt-to-equity ratio of 1.86.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.22. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%. The business had revenue of $19.04 million during the quarter, compared to the consensus estimate of $12.88 million. research analysts expect that Recro Pharma will post -3.02 EPS for the current year.

In related news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total transaction of $2,014,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 21.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its holdings in Recro Pharma by 42.5% in the third quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock valued at $220,000 after buying an additional 7,308 shares in the last quarter. JT Stratford LLC increased its holdings in Recro Pharma by 7.8% in the fourth quarter. JT Stratford LLC now owns 112,265 shares of the specialty pharmaceutical company’s stock valued at $1,038,000 after buying an additional 8,120 shares in the last quarter. Cadence Capital Management LLC increased its holdings in Recro Pharma by 7.8% in the fourth quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock valued at $1,672,000 after buying an additional 13,078 shares in the last quarter. BlackRock Inc. increased its holdings in Recro Pharma by 1.4% in the fourth quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock valued at $9,359,000 after buying an additional 13,799 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 14,098 shares in the last quarter. 57.85% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/recro-pharma-reph-earns-buy-rating-from-oppenheimer.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply